Lindy Biosciences Enters Licensing and Collaboration Agreement With Novartis for Multi-target Drug Delivery Innovation

  • Novartis secures exclusive global rights across multiple biologic targets to Lindy Biosciences' microglassification technology
  • Collaboration aims to enable high-concentration self-administered drug treatments, improving patient outcomes and compliance
  • Lindy Biosciences to receive an upfront payment of US$20 million and eligible to receive up to US$934 million in milestone payments plus tiered royalties

Lindy Biosciences , a pioneering biotechnology company specializing in innovative drug formulation and delivery technologies, today announced a multi-target exclusive global licensing agreement and strategic collaboration with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE: NVS), an innovative medicines company.

The collaboration will focus on transitioning select innovative medicines from the Novartis portfolio to convenient, self-administered subcutaneous injections using Lindy Biosciences' proprietary microglassification suspension technology. By delivering high concentrations of biologics, this technology significantly increases the maximum dose that can be administered in a single subcutaneous injection. This has the potential to reduce healthcare costs while also improving patient comfort, convenience, and treatment compliance.

Currently, over half of all antibody therapeutics are administered intravenously in a clinical setting, primarily due to the high doses required that cannot be formulated in volumes suitable for subcutaneous injection. Lindy Biosciences' proprietary microglassification platform technology is poised to transform this paradigm by enabling self-administration at home via pre-filled syringes or autoinjectors.

Strategic Impact and Future Outlook

Dr. Deborah Bitterfield, founder and CEO of Lindy Biosciences, expressed enthusiasm about the collaboration: "We're excited to deepen our collaboration with Novartis. This collaboration is a testament to our shared dedication to enhancing patient care and marks a significant milestone as we take Lindy's formulation technology into the clinic for the first time. Together, we aim to transform drug delivery and improve treatment access for patients worldwide."

The agreement's financial terms include an upfront payment of US$20 million to Lindy Biosciences. Lindy Biosciences is also eligible to receive up to US$934 million in additional payments across multiple targets upon achieving certain regulatory, development and commercial milestones as well as tiered single-digit royalties on net sales.

This collaboration marks a significant step forward in addressing the growing need for patient-friendly treatment options that can be self-administered at home. By combining innovative technology from Lindy Biosciences and the global reach and expertise of Novartis, the collaboration promises to usher in a new era of drug delivery, reshaping patient care on a global scale.

About Lindy Biosciences

Lindy Biosciences is dedicated to transforming the delivery of biologic drugs and improving patients' lives through innovative biotherapeutic formulations. Our cutting-edge solutions are designed to enhance drug formulation and delivery, specializing in the subcutaneous administration of concentrated (>400 mg/mL) biologic suspensions.

Founded in 2016 and headquartered in Morrisville, NC, Lindy Biosciences leverages core microglassification technology originated at Duke University and further developed by the company. We are committed to partnering with leading pharmaceutical companies to advance treatment accessibility for patients worldwide.

For more information, visit us at www.lindybio.com or follow us on LinkedIn .

media@lindybio.com

News Provided by Business Wire via QuoteMedia

NVS
The Conversation (0)
Excalibur Engages Precision GeoSurveys for Airborne Geophysical Survey at Bellehelen

Excalibur Engages Precision GeoSurveys for Airborne Geophysical Survey at Bellehelen

Excalibur Metals Corp. (TSXV: EXCL,OTC:EXCBF) (OTCQB: EXCBF) ("Excalibur" or the "Company") is pleased to announce that it has engaged Precision GeoSurveys US Inc. ("Precision") to conduct a high-resolution helicopter-borne magnetic and radiometric survey at the Company's Bellehelen Silver-Gold... Keep Reading...
Nevada Sunrise Completes Ground Gravity Survey at the Fivemile Gold Project, Cortez Mining District, Nevada

Nevada Sunrise Completes Ground Gravity Survey at the Fivemile Gold Project, Cortez Mining District, Nevada

Nevada Sunrise Metals Corporation (TSXV: NEV,OTC:NVSGF) (OTC Pink: NVSGF) ("Nevada Sunrise" or the "Company") is pleased to announce the completion of a ground gravity survey program (the "Survey") at the Fivemile Gold Project ("Fivemile", or the "Project"), located within the Battle... Keep Reading...
Metalsource Mining Intersects 22 Metres of Mineralization in Major Southern Step Out at Silver Hill

Metalsource Mining Intersects 22 Metres of Mineralization in Major Southern Step Out at Silver Hill

SH26-45 intersects approximately 22 metres (core length) of mineralization, 80 metres south of SH26-27, with assays pending, as Metalsource advances toward significantly larger stepouts to test the broader scale of the Silver Hill system. Metalsource Mining Inc. (CSE: MSM) (OTCQB: MSMMF) (FSE:... Keep Reading...
Excalibur Reports Gravity Survey Results from Rangefront Target at Bellehelen

Excalibur Reports Gravity Survey Results from Rangefront Target at Bellehelen

Excalibur Metals Corp. (TSXV: EXCL,OTC:EXCBF) (OTCQB: EXCBF) ("Excalibur" or the "Company") is pleased to report results from its ground gravity survey at the Rangefront Target ("Rangefront") at the Company's Bellehelen Silver-Gold Project ("Bellehelen" or the "Project"), Nye County, Nevada.The... Keep Reading...
Metalsource Mining Launches Major Step Out Program With 1.1 km Northern Target to Test Broader Scale of Silver Hill

Metalsource Mining Launches Major Step Out Program With 1.1 km Northern Target to Test Broader Scale of Silver Hill

Phase 2 expands beyond Silver Hill proper while SH26-34 intersects approximately 20 metres of mineralization in drill core, including multiple massive sulphide intervals with assays pending. Surface mineralization and correlated IP anomalies strengthen the case for broader expansion. Metalsource... Keep Reading...
Canada maple leaves on left and pharmaceutical pills in red and blue on right.

5 Best-performing Canadian Pharma Stocks in 2026

From established players to up-and-coming firms, Canada's pharmaceutical landscape is diverse and dynamic.Canadian drug companies are working to discover, develop and commercialize major innovations amid an increasingly competitive global landscape. Rising technologies such as artificial... Keep Reading...
Large pharmaceutical pill with gold dollar sign in the middle. Stock tickers and charts in the background.

Top 5 Small-cap Pharma Stocks in 2026

Today's pharmaceutical stocks are facing the challenges of government-imposed drug price caps, waning demand for COVID-19 vaccines and global stock market upheaval. However, the industry's major underlying drivers — higher rates of cancer and chronic disease — are still at play and not expected... Keep Reading...
Marvel Announces Final Shank3 Data: MB-204 Highly Effective at Reversing Autism Behaviours

Marvel Announces Final Shank3 Data: MB-204 Highly Effective at Reversing Autism Behaviours

Marvel Biosciences Corp. (TSXV: MRVL | OTCQB: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), a drug discovery company developing novel therapeutics for autism spectrum disorder ("ASD") and related neurodevelopmental disorders, is... Keep Reading...
Medical professional's hand under a digital interface with a glowing cross and circuit design.

Eli Lilly Brings AI to Drug Delivery in METiS TechBio Deal

METiS TechBio (HKEX:7666) could collect up to US$1.1 billion in milestone payments from Eli Lilly and Company (NYSE:LLY) under a new research pact to design lipid nanoparticles that carry medicines to specific tissues in the body.Lipid nanoparticles, or LNPs, carry therapeutic payloads to target... Keep Reading...
BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting

BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting

briacell therapeutics corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority-owned subsidiary, BriaPro Therapeutics Corp. ("BriaPro"), today announced that four... Keep Reading...

Interactive Chart

Latest Press Releases

Related News